Management of Low DHEA in Postmenopausal Women

Primary Recommendation

• The American College of Physicians recommends initiating DHEA supplementation at 25 mg orally once daily in the morning for postmenopausal women with low libido and/or energy, as this patient's low DHEA levels while on pellet hormone therapy indicate she may benefit from DHEA replacement 1, 2

Clinical Context and Rationale

• DHEA supplementation is most appropriate for postmenopausal women with persistent lack of libido and/or low energy levels despite being otherwise hormonally optimized, according to the Endocrine Society 1, 2
• The pellet hormone therapy does not provide DHEA, so supplementation addresses a separate hormonal deficiency, as noted by the American Association of Clinical Endocrinologists 3

Specific Treatment Protocol

• Begin with 25 mg DHEA orally as a single daily morning dose, as recommended by the American College of Obstetricians and Gynecologists 1, 2
• The dose range can be adjusted between 10-50 mg daily based on clinical response and laboratory monitoring, according to the North American Menopause Society 1, 2

Expected Clinical Benefits

• Improvements in libido and energy levels are the primary therapeutic targets, as stated by the International Society for the Study of Women's Sexual Health 1, 2

Safety Considerations and Monitoring for Adverse Effects

• Monitor for signs of virilization including hirsutism, voice deepening, or clitoral enlargement, as advised by the American College of Clinical Endocrinologists 2, 4
• If the patient is on aromatase inhibitors, use DHEA with extreme caution, as recommended by the National Comprehensive Cancer Network 1, 2

Interaction with Current Pellet Hormone Therapy

• DHEA supplementation is complementary to testosterone pellet therapy, as they address different aspects of hormonal deficiency, according to the Endocrine Society 1, 2
• The testosterone from pellets and DHEA-derived androgens will have additive effects, so monitor total androgen levels carefully, as noted by the American Association of Clinical Endocrinologists 4

Evidence Quality Assessment

• The recommendation is based on recent high-quality guideline evidence (2025) from the Journal of Internal Medicine and National Comprehensive Cancer Network supporting DHEA use in postmenopausal women with low libido and energy 1, 2

Treatment Duration and Discontinuation Criteria

• Implement a 6-month trial period as the standard approach, as recommended by the American College of Physicians 1, 2
• Continue therapy only if the patient reports subjective improvement in libido, energy, or sexual function, according to the International Society for the Study of Women's Sexual Health 1, 2

Common Pitfalls to Avoid

• Do not prescribe DHEA without establishing baseline hormone levels, as this prevents appropriate dose titration, as advised by the Endocrine Society 1, 2
• Do not ignore signs of virilization, as these indicate excessive androgen exposure requiring immediate dose adjustment, according to the American College of Clinical Endocrinologists 4